Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference
16 févr. 2021 16h05 HE
|
Morphic Therapeutic
WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Expands Research and Development Collaboration with Janssen Through Third Integrin Program
05 janv. 2021 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass. , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference
30 déc. 2020 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Dec. 30, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced that Praveen Tipirneni, M.D.,...
Morphic Therapeutic Announces Appointment of Dr. Martin W. Edwards as Member of its Board of Directors
04 déc. 2020 08h00 HE
|
Morphic Therapeutic
WALTHAM, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing oral integrin therapies, today announced the appointment of Dr. Martin W....
Morphic Therapeutic to Present at the Jefferies Virtual London Healthcare Conference
17 nov. 2020 09h05 HE
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Morphic Announces Corporate Highlights and Third Quarter 2020 Financial Results
09 nov. 2020 07h00 HE
|
Morphic Therapeutic
Initiated phase 1 clinical trial for MORF-057 with results expected by mid-2021 Presented data at UEG 2020 that reinforce preclinical potency and selectivity profile of MORF-057 Received $20 million...
Morphic Announces Presentation of New Data Supporting Development of MORF-057 at UEG Week Virtual 2020
12 oct. 2020 07h00 HE
|
Morphic Therapeutic
-Data validate physiologically relevant assay used in MORF-057 Phase 1 studies to measure receptor occupancy of α4β7 integrin--MORF-057, inhibitor of α4β7 integrin, in development to treat...
Morphic Therapeutic Announces First Healthy Volunteers Dosed in Phase 1 Clinical Trial of MORF-057
23 sept. 2020 06h30 HE
|
Morphic Therapeutic
First orally available integrin inhibitor from MInT Platform to enter the clinicMORF-057, inhibitor of α4β7 integrin, in development to treat inflammatory bowel diseasePhase 1 program to assess safety...
Morphic Therapeutic to Present at the Jefferies Next Generation IBD Therapeutics Virtual Summit
21 sept. 2020 16h45 HE
|
Morphic Therapeutic
WALTHAM, Mass., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Morphic Announces Participation in Upcoming Investor Conferences
03 sept. 2020 16h30 HE
|
Morphic Therapeutic
WALTHAM, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...